

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
CLINICAL TRIAL OF THE ITERATIVE-PROCESS
HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES
VACCINE APPROVED
FURTHER CEMENTING OUR LEADING POSITION IN
GLOBAL RABIES VACCINE INDUSTRY

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The clinical trial approval for the human diploid rabies vaccine developed by the Group has been recently obtained from the National Medical Products Administration. This product, as an iterative upgraded human diploid rabies vaccine, is featured with super highly-effective characteristics, and also marks a significant iterative upgrading in technology for the global rabies vaccine industry. Results from animal testing show that the Group’s human diploid rabies vaccine triggers a high level of antibodies that provide sufficient protection after immunization. Under the same dosage, the potency of the Group’s human diploid rabies vaccine is significantly higher than that of those marketed human diploid rabies vaccines.

Rabies is the most deadly disease in the world, with a fatality rate of nearly 100%. Currently, there is a lack of effective treatment for rabies in clinical practice, therefore, post-exposure prevention is crucial, and the main preventive measure is vaccination against human rabies.

Compared with the traditional Vero cell rabies vaccines, human diploid rabies vaccine uses human diploid cells instead of Vero cells, which are homologous to humans and have a natural safety advantage. The human diploid rabies vaccine currently available in the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, with higher product added value.

Compared with the traditional human diploid rabies vaccines of the first generation, the iterative-process highly-effective human diploid rabies vaccine developed by the Group has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in the traditional process. It has been optimized and innovated in the purification process with the product quality and safety significantly improved.

Compared with the number of traditional rabies vaccinations, this product developed by the Group can be vaccinated with either “five-needle approach”, “simple four-needle approach” or “2-1-1 four-needle approach”, which is more flexible and convenient.

The Group has completed the construction of an iterative-process highly-effective human diploid rabies vaccine workshop that meets international standards, and has completed the production of commercial-scale Phase III clinical trial samples, which is capable of producing this product in large scale.

The human diploid rabies vaccine is the WHO’s gold standard for rabies vaccines, which has been widely applied in many developed countries. As the world’s second largest supplier of rabies vaccines, the Group is committed to leading the in-depth technology iteration and upgrading of rabies vaccines globally and providing the market with a series of rabies vaccine products with better quality and higher safety, thereby promoting the sustainable development of the Group. Obtaining the clinical trial approval for the iterative-process highly-effective human diploid rabies vaccine will further cement the Group’s leading position in global rabies vaccine industry.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, March 9, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.